ReviewBiomarker insights2025
Advancing Clinical Use of Neurofilament Light Chain: Translational Insights From Research to Routine Practice.
Review in Biomarker insights, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Visualized knowledge mapping on the current research trends and emerging areas of neuroimmune modulation in the past two decades.Frontiers in immunology · 2025Pooled it
- Real-world Roche ElecsysJournal of neurology · 2026Article
- Neurofilament Light Chain (NfL) in Neurodegenerative Diseases: Biological and Clinical Significance, Multi-Omics Integration, and AI-Driven Biomarker Modeling for Precision Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Changes in Serum GDF-15 in Relation to the Onset of Post-Stroke Depression After Acute Ischemic Stroke and the Development of a Comprehensive Prediction Model.Actas espanolas de psiquiatria · 2026Article
- Blood-Derived Inflammatory Indices Across Essential Tremor, Parkinson's Disease, and Progressive Supranuclear Palsy: An Exploratory Retrospective Analysis.Diseases (Basel, Switzerland) · 2026Article
- Association of neurofilament light chain, CXCL9, IL-6, and TNFRSF11B with intrinsic capacity in community-dwelling older adults.GeroScience · 2026Article
- Establishing a standardized biorepository across 3 clinical and translational science center-affiliated veterinary institutions is feasible and productive.American journal of veterinary research · 2026Article
- Bayes at the Bedside: Biomarkers in Situations of Clinical Uncertainty.Diagnostics (Basel, Switzerland) · 2026Article
- Neurodegenerative and inflammatory biomarkers are detectable in saliva in multiple sclerosis.Scientific reports · 2026Article
- Serum neurofilament light chain (sNFL) as a predictive biomarker for Chemotherapy-induced peripheral neurotoxicity (CIPN): consideration of current evidence, validation steps, and barriers to CIPN biomarker implementation in clinical practice-a narrative review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- Fetal MRI Biomarkers and the Prenatal Origins of Autism Spectrum Disorder: A Narrative Review.Journal of clinical medicine · 2026Review
- Serum neurofilament light chain in multiple sclerosis: from biological signal to clinically informed decision-making.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurofilament Light Chain (NfL) has emerged as a promising biomarker for neurological diseases. NfL, a structural component of axons, is released into cerebrospinal fluid (CSF) and blood following neuro-axonal damage. Highly sensitive immunometric assays have enabled its reliable quantification in blood, facilitating non-invasive monitoring. Several studies demonstrated strong correlations between NfL levels and the risk of developing different neurological diseases and, in individuals already living with a neurological disease, with the risk of worsening. However, interpretation is affected by factors like age, BMI, renal function, and comorbidities. NfL is already utilized as a diagnostic and prognostic biomarker in clinical practice, particularly in specialized centers and research settings, although no FDA-cleared assay is currently available for routine use. Recent research has highlighted that NfL may represent the first of a new generation of neurological biomarkers, with many more ready to come, such as glial fibrillary acidic protein (GFAP), further improving diagnostic and prognostic accuracy. Despite its promising role in the landscape of biomarkers, challenges remain to implement NfL in daily clinical practice, including standardization of assays, defining reference values, and ensuring methodological consistency. Addressing these limitations will be essential for integrating NfL into routine clinical practice, ultimately advancing precision medicine in neurology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.